Alimentiv and Dova Health Launch AI-Powered Tool for Enhanced Ulcerative Colitis Assessment in Clinical Trials

Alimentiv, a global full-service gastrointestinal (GI) contract research organization (CRO), and Dova Health Intelligence (formerly Satisfai Health), a Vancouver-based software company specializing in AI applications for GI disease assessment, have announced the commercial launch of DovaVision™ at the 2025 Digestive Disease Week (DDW) in San Diego. This AI-driven tool, designed specifically for clinical trials focusing on ulcerative colitis (UC), provides frame-level analysis and quantification of disease severity, enhancing the depth and consistency of imaging data. Key Developments and Insights DovaVision™ is an advanced endoscopy reading tool that uses artificial intelligence to analyze and score endoscopy videos for UC clinical trials. The system is particularly innovative because it reveals and quantifies subtle changes in disease severity, which are often difficult to detect through manual scoring methods alone. This technology offers researchers and sponsors more detailed and actionable insights, improving the overall quality of data generated during clinical studies. The development of DovaVision™ involved extensive collaboration between Dova and Alimentiv. Dova utilized a large, anonymized global dataset of inflammatory bowel disease (IBD) colonoscopy videos. These videos were meticulously labeled and interpreted by Alimentiv's team of expert central readers and medical professionals who specialize in IBD disease assessment and scoring. The combination of state-of-the-art AI algorithms and clinical expertise ensures that DovaVision™ delivers accurate and reliable results. One of the primary advantages of DovaVision™ is its ability to generate consistent, frame-level analysis of endoscopy videos. This level of detail allows for a more comprehensive understanding of disease activity and treatment responses, which can be crucial in the development of new therapies. The tool's raw data outputs can also be integrated with other clinical datasets, enabling researchers to correlate visual imaging biomarkers with patient outcomes and provide deeper mechanistic insights. Commercial Availability and Integration DovaVision™ is now commercially available and will be incorporated into Alimentiv’s proprietary multi-modal imaging review platform, Notō™. This integration offers a seamless end-to-end solution for medical image-based analysis and scoring, enhancing the capabilities of Alimentiv's medical imaging portfolio. Notō™ is designed to support all stages of clinical trials, from Phase I through Phase IV, ensuring that sponsors have access to the most advanced and detailed analysis possible. Industry Reactions and Expert Opinions Solveig Johannessen, CEO of Dova Health Intelligence, emphasized the importance of DovaVision™ in the context of precision medicine. "In the era of precision medicine, successful clinical trials require more than just categorical scores; they need data-driven insights. With DovaVision™, we're applying explainable AI to endoscopy video data to reveal additional understanding of gastrointestinal disease activity and treatment response," she stated. Dr. Michael Byrne, founder and chairman of Dova, highlighted the practical benefits of the technology. "As a gastroenterologist, I know that detecting and quantifying subtle changes in endoscopic disease activity can significantly impact the outcomes of clinical trials. DovaVision™ not only delivers consistent, frame-level analysis but also integrates with other clinical datasets, providing a holistic view of patient data." Pierre Gaudreault, CEO of Alimentiv, shared his enthusiasm about the partnership and the potential of DovaVision™. "We are very excited to bring this enhanced video analysis capability into Alimentiv's medical imaging portfolio. By making this cutting-edge AI technology available to our sponsors, we will continue to lead the industry with more detailed analysis, competitive trial costs, and faster timelines." Impact and Future Prospects The introduction of DovaVision™ represents a significant advancement in the field of UC research and clinical trials. By leveraging AI to provide more detailed and consistent evaluations, the tool can help streamline the clinical trial process, reduce costs, and speed up the development of new treatments. This technology has the potential to set new standards in endoscopic assessment, making it a valuable asset for both researchers and sponsors in the pharmaceutical and biotechnology industries. Company Profiles Alimentiv, Inc.: Founded in 1986, Alimentiv is a leading specialty GI-focused CRO that provides clinical, medical imaging, and precision medicine services to the pharmaceutical and biotechnology sectors. The company is dedicated to advancing the development of novel therapies and accelerating their time to market. Alimentiv operates globally, with headquarters in London, Ontario, Canada, and a presence across North America, Europe, Asia-Pacific, and Latin America. Dova Health Intelligence Inc.: A precision health technology company based in Canada, Dova specializes in AI-powered solutions for gastrointestinal care and research. The company's focus on computer vision and data-driven diagnostics has led to the development of tools that enhance clinical decision-making and improve patient outcomes. Dova continues to expand its product suite, including DovaVision™ and DovaSound, and collaborates with leading researchers, clinicians, and industry partners to deliver actionable insights. Industry Evaluation Industry insiders are optimistic about the impact of DovaVision™ on UC clinical trials. The tool's ability to automate and standardize the scoring process is expected to increase the reliability and reproducibility of trial data. Moreover, the integration of visual imaging biomarkers with other clinical data points will enable a more nuanced understanding of disease dynamics and therapeutic efficacy. This technological advancement could accelerate the discovery of new treatments and improve patient care, solidifying the role of AI in medical research and drug development.